Allegheny Health Network's Dr. Salman Fazal Named Castle Connolly Top Doctor for 2024
TL;DR
Dr. Fazal has been recognized as a 2024 Castle Connolly Top Doctor, putting him in the top 7% of the nation's licensed physicians.
Dr. Fazal specializes in diagnosing and treating complex blood/bone-marrow cancers in adults, using stem-cell transplants and cellular therapies.
Dr. Fazal's work offers promising treatment options, personalized care, and ongoing research into new therapeutic targets for blood cancer patients.
Advances in genomics, cellular therapies, immunotherapy, and targeted therapies have transformed treatment options for blood cancers, according to Dr. Fazal.
Found this article helpful?
Share it with your network and spread the knowledge!

Dr. Salman Fazal, a hematologist-oncologist specializing in blood cancers at Allegheny Health Network (AHN), has been named a 2024 Castle Connolly Top Doctor. This marks the first time Dr. Fazal has received this esteemed recognition, which is awarded to only about 7 percent of licensed physicians annually.
As the director of transplant and cellular therapies at AHN Cancer Institute since 2018, Dr. Fazal focuses on treating complex blood and bone marrow cancers, including leukemia, lymphoma, and myeloma. His expertise extends to advanced treatments such as stem-cell transplants and innovative cellular therapies that harness the immune system to combat cancer.
Dr. Fazal's recognition underscores the significant advancements in blood cancer treatment. He emphasizes the importance of personalized, multidisciplinary approaches tailored to each patient's unique condition. The emergence of immune-based treatments like CAR T-cell therapy has been particularly groundbreaking for aggressive lymphomas and leukemias.
"The future of blood cancer treatment is promising, with ongoing research into new therapeutic targets and further refinement of immunotherapies," Dr. Fazal states, highlighting the critical role of clinical trials in advancing treatment options. Despite these technological advancements, he maintains that attentive patient care remains fundamental to his practice.
Dr. Fazal's selection as a Top Doctor reflects the high regard in which he is held by his peers. The Castle Connolly research team, led by physicians, carefully selects honorees based on criteria including medical education, training, hospital appointments, and disciplinary histories.
This recognition not only celebrates Dr. Fazal's individual achievements but also shines a light on the collaborative nature of healthcare. It underscores the importance of multidisciplinary teams in providing comprehensive cancer care and advancing treatment options for patients with complex blood cancers.
As the field of hematology-oncology continues to evolve rapidly, Dr. Fazal's recognition as a Top Doctor serves as a testament to the cutting-edge care available at Allegheny Health Network. It also highlights the ongoing progress in the fight against blood cancers, offering hope to patients and their families facing these challenging diagnoses.
Curated from 24-7 Press Release

